Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lilly

- PMLiVE

Another $2m donated to further neurodegenerative commitment

Research funders build on global initiative for brain deteriorating diseases

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

Eli Lilly HQ

Lilly eyes pivotal trials for pain drug tanezumab in 2015

Drug was placed under clinical hold by FDA in 2010

Biogen Idec building

Biogen Idec plans phase III Alzheimer’s trial before year-end

And MS drugs drive 2014 sales          

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links